Pepgen inc. presents pgn-edodm1 preclinical data supporting the company's enhanced delivery oligonucleotide platform and pgn-edodm1 program at two medical conferences

- edo platform observed to drive 25-fold higher level of oligonucleotide delivery to myotube nuclei compared to “naked” oligonucleotide -

PEPG Ratings Summary

PEPG Quant Ranking